Efficacy and Safety of Epirubicin Combined with Temozolomide for Treatment of Advanced Leiomyosarcoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.2144229313949
   PubMed Web of Science ®Google Scholar
• Liu W, Jiang Q, Zhou Y. Advances of systemic treatment for adult soft-tissue sarcoma. Chin Clin Oncol. 2018;7(4):42. doi:10.21037/cco.2018.08.0230173532
   PubMed Web of Science ®Google Scholar
• Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: an analysis of 26,758 cases. Int J Cancer. 2006;119(12):2922–2930. doi:10.1002/ijc.2223917013893
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38(4):543–549. doi:10.1016/S0959-8049(01)00398-711872347
   PubMed Web of Science ®Google Scholar
• Wile AG, Evans HL, Romsdahl MM. Leiomyosarcoma of soft tissue: a clinicopathologic study. Cancer. 1981;48(4):1022–1032. doi:10.1002/1097-0142(19810815)48:4<1022::AID-CNCR2820480429>3.0.CO;2-57272926
   PubMed Web of Science ®Google Scholar
• Nathan H, Raut CP, Thornton K, et al. Predictors of survival after resection of retroperitoneal sarcoma: a population-based analysis and critical appraisal of the AJCC staging system. Ann Surg. 2009;250(6):970–976. doi:10.1097/SLA.0b013e3181b2518319644351
   PubMed Web of Science ®Google Scholar
• Brennan MF, Antonescu CR, Maki RG. Management of Soft Tissue Sarcoma. 2nd ed. New York: Springer; 2016:3–17.
   Google Scholar
• Gustafson P, Willén H, Baldetorp B, Fernö M, Akerman M, Rydholm A. Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content. Cancer. 1992;70(1):114–119. doi:10.1002/1097-0142(19920701)70:1<114::AID-CNCR2820700119>3.0.CO;2-U1606532
   PubMed Web of Science ®Google Scholar
• Farshid G, Goldblum J, Weiss SW. Leiomyosarcoma of soft tissue: a tumor of vascular origin with multivariate analysis of outcome. Mod Pathol. 2003;16(8):778–785. doi:10.1097/01.MP.0000083648.45923.2B12920222
   PubMed Web of Science ®Google Scholar
• Patel PM, Suciu S, Mortier L, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer. 2011;47(10):1476–1483. doi:10.1016/j.ejca.2011.04.03021600759
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158–166. doi:10.1200/JCO.2000.18.1.15810623706
   PubMed Web of Science ®Google Scholar
• Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest. 2003;21(6):821–829. doi:10.1081/CNV-12002508414735685
   PubMed Web of Science ®Google Scholar
• Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 2003;98(9):1942–1946. doi:10.1002/cncr.1173014584078
   PubMed Web of Science ®Google Scholar
• Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 2003;98(12):2693–2699. doi:10.1002/cncr.1187514669291
   PubMed Web of Science ®Google Scholar
• Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005;104(8):1706–1712. doi:10.1002/cncr.2138416134177
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870–877. doi:10.1016/S0959-8049(01)00050-811313175
   PubMed Web of Science ®Google Scholar
• D’Ambrosio L, Touati N, Blay JY, et al. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer. 2020;126(11):2637–2647. doi:10.1002/cncr.3279532129883
   PubMed Web of Science ®Google Scholar
• van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi:10.1016/S0140-6736(12)60651-522595799
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-376629895706
   PubMed Web of Science ®Google Scholar
• Chi Y, Yao Y, Wang S, et al. Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo-controlled and multi-centered clinical trial. J Clin Oncol. 2018;36(15_suppl):11503. doi:10.1200/JCO.2018.36.15_suppl.11503
   Web of Science ®Google Scholar
• Mir O, Brodowicz T, Italiano A, et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Oncol. 2016;17(12):1732–1742. doi:10.1016/S1470-2045(16)30507-127751846
   PubMed Web of Science ®Google Scholar
• Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, Jazaeri AA. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer. 2010;20(1):120–125. doi:10.1111/IGC.0b013e3181c7fe5320130512
   PubMed Web of Science ®Google Scholar
• Bujko M, Kowalewska M, Danska-Bidzinska A, Bakula-Zalewska E, Siedecki JA, Bidzinski M. The promoter methylation and expression of the O6-methylguanine-DNA methyltransferase gene in uterine sarcoma and carcinosarcoma. Oncol Lett. 2012;4(3):551–555. doi:10.3892/ol.2012.77122970054
   PubMed Web of Science ®Google Scholar
• Oza J, Doshi SD, Hao L, Musi E, Schwartz GK, Ingham M. Homologous recombination repair deficiency as a therapeutic target in sarcoma. Semin Oncol. 2020;47(6):380–389. doi:10.1053/j.seminoncol.2020.10.00233183763
   PubMed Web of Science ®Google Scholar
• Khusnutdinov RR, Boichuk SV. Mechanisms of sensitivity of soft tissue sarcoma cells to temozolomide. Bull Exp Biol Med. 2017;163(2):260–262. doi:10.1007/s10517-017-3779-x28726196
   PubMed Web of Science ®Google Scholar